Teva Pharmaceutical Industries Ltd.

Teva's DuoResp Spiromax® Wins Leading Award for Medical Design Excellence

Amsterdam (ots/PRNewswire) - Teva Pharmaceutical Industries Ltd. today announced that its DuoResp Spiromax(R) inhaler has won silver at the 2015 Medical Design Excellence Awards (MDEA). The awards recognize significant advances in medical product design that improve the quality of healthcare delivery. DuoResp Spiromax(R) (budesonide/formoterol fumarate dihydrate) is a new multi-dose dry-powder inhaler for the management of asthma and chronic obstructive pulmonary disease (COPD).

"Innovative, patient-focused design is extremely important at a time when real-world behaviors and outcomes are what count," said Rob Koremans, MD., President and CEO, Teva Global Specialty Medicines. "We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax."

Many people with asthma and COPD are inadequately controlled as a consequence of poor inhaler technique which can lead to suboptimal outcomes in clinical practice and daily life.

DuoResp Spiromax(R) represents a step forward in supporting improved inhaler technique and disease control. It contains a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist for the relief of bronchoconstriction in asthma and COPD. With its design, the Spiromax(R) inhaler incorporates a specific combination of features and provides consistent drug delivery across inspiratory flow rates. DuoResp Spiromax(R) received marketing authorization from the European Commission on the 29th of April 2014, and is currently available to patients in multiple countries across Europe.

About Asthma and COPD in Europe 

Twenty million people in European Union are living with asthma, with an estimated 82,000 hospital admissions each year costing some EUR33.9 billion. COPD affects 23 million people in Europe, resulting in 1.1 million hospital admissions annually and estimated indirect and direct costs of EUR48.4 billion.

About the Medical Design Excellence Awards 

The Medical Design Excellence Awards (http://www.MDEAwards.com) is the only awards program that exclusively recognizes contributions to and advances in the design of medical products. Entries undergo a comprehensive evaluation by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics. Awards are given based on design and engineering features, including innovative use of materials; user-related functions that improve healthcare delivery and change traditional medical attitudes or practices; features that provide enhanced benefits to the patient; and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

About Teva  

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit http://www.tevapharm.com.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: 

This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially Copaxone(R) (including competition from orally-administered alternatives, as well as from potential purported generic equivalents) and our ability to migrate users to our 40 mg/mL version; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. 

Contact:

IR Contacts: Kevin C. Mannix, United States, (215) 591-8912 / Ran
Meir, United States, +1-(215) 591-3033 / Tomer Amitai, Israel, +972
(3)
926-7656 / PR Contacts: Iris Beck Codner, Israel, +972 (3) 926-7687 /
Denise Bradley, United States, +1-(215) 591-8974, Nancy Leone, United
States, +1-(215) 284-0213



Das könnte Sie auch interessieren: